New anti-IL-7Rα monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models (Q92797801)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31439943 AND SRC:MED&resulttype=core&format=json

1 May 2020

title

New anti-IL-7Rα monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31439943 AND SRC:MED&resulttype=core&format=json

1 May 2020

main subject

lymphoblastic leukemia

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31439943 AND SRC:MED&resulttype=core&format=json

1 May 2020

author name string

Julie A Hixon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31439943 AND SRC:MED&resulttype=core&format=json

1 May 2020

Caroline Andrews

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31439943 AND SRC:MED&resulttype=core&format=json

1 May 2020

Lila Kashi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31439943 AND SRC:MED&resulttype=core&format=json

1 May 2020

Casey L Kohnhorst

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31439943 AND SRC:MED&resulttype=core&format=json

1 May 2020

Emilee Senkevitch

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31439943 AND SRC:MED&resulttype=core&format=json

1 May 2020

Kelli Czarra

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31439943 AND SRC:MED&resulttype=core&format=json

1 May 2020

Wenqing Li

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31439943 AND SRC:MED&resulttype=core&format=json

1 May 2020

Joel P Schneider

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31439943 AND SRC:MED&resulttype=core&format=json

1 May 2020

Scott T R Walsh

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31439943 AND SRC:MED&resulttype=core&format=json

1 May 2020

Scott K Durum

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31439943 AND SRC:MED&resulttype=core&format=json

1 May 2020

publication date

22 August 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31439943 AND SRC:MED&resulttype=core&format=json

1 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31439943 AND SRC:MED&resulttype=core&format=json

Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group (TCCSG) Study L04-16.

1 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

The changing scene of adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

How I treat relapsed childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Interleukin-7 receptor expression: intelligent design

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1).

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

IL-7 contributes to the progression of human T-cell acute lymphoblastic leukemias.

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Interleukin 7 and thymic stromal lymphopoietin: from immunity to leukemia

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Crystallization and preliminary X-ray diffraction of human interleukin-7 bound to unglycosylated and glycosylated forms of its alpha-receptor

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Structural and biophysical studies of the human IL-7/IL-7Ralpha complex

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Characterization of an interleukin-7-dependent thymic cell line derived from a p53(-/-) mouse

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo Expanded Autologous NK Cells.

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations.

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains.

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL).

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Generation of human acute lymphoblastic leukemia xenografts for use in oncology drug discovery.

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts.

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

"Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions"-Treatment of ALL.

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Interleukin-7 up-regulates cyclin D1 via activator protein-1 to promote proliferation of cell in lung cancer

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Interleukin-7 (IL-7) in colorectal cancer: IL-7 is produced by tissues from colorectal cancer and promotes preferential expansion of tumour infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Interleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell lines

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Mutant IL-7Rα and mutant NRas are sufficient to induce murine T cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038/S41375-019-0531-8

7 January 2021

10.1038/S41375-019-0531-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31439943 AND SRC:MED&resulttype=core&format=json

1 May 2020

1 reference